James E. Wooldridge

3.5k total citations
63 papers, 2.7k citations indexed

About

James E. Wooldridge is a scholar working on Pathology and Forensic Medicine, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, James E. Wooldridge has authored 63 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pathology and Forensic Medicine, 22 papers in Genetics and 21 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in James E. Wooldridge's work include Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Monoclonal and Polyclonal Antibodies Research (18 papers). James E. Wooldridge is often cited by papers focused on Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Monoclonal and Polyclonal Antibodies Research (18 papers). James E. Wooldridge collaborates with scholars based in United States, France and United Kingdom. James E. Wooldridge's co-authors include George J. Weiner, Arthur Μ. Krieg, Brian K. Link, Hsin-Ming Liu, Christopher E. Dahle, Zuhair K. Ballas, Charles F. Lynch, Valerie L. Forman‐Hoffman, Elizabeth A. Chrischilles and Bernd Jahrsdörfer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

James E. Wooldridge

62 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James E. Wooldridge United States	23	1.3k	968	745	663	641	63	2.7k
Neil L. Berinstein Canada	29	1.3k 1.0×	887 0.9×	1.1k 1.5×	792 1.2×	582 0.9×	104	2.9k
Richard J. Bende Netherlands	27	1.3k 1.0×	1.0k 1.0×	472 0.6×	927 1.4×	573 0.9×	51	3.3k
Leonardo Flenghi Italy	24	975 0.8×	1.5k 1.5×	876 1.2×	536 0.8×	475 0.7×	36	2.7k
DG Maloney United States	23	1.2k 1.0×	1.3k 1.4×	1.1k 1.5×	567 0.9×	882 1.4×	37	3.1k
Simon D. Wagner United Kingdom	33	1.2k 0.9×	673 0.7×	676 0.9×	981 1.5×	599 0.9×	104	3.0k
Hinrich P. Hansen Germany	29	1.5k 1.2×	538 0.6×	949 1.3×	1.3k 2.0×	211 0.3×	72	3.2k
T C Meeker United States	22	619 0.5×	820 0.8×	986 1.3×	822 1.2×	570 0.9×	29	2.3k
Roland Repp Germany	36	2.2k 1.7×	1.1k 1.2×	1.4k 1.9×	1.1k 1.6×	615 1.0×	85	4.3k
Jon Arnason United States	27	1.4k 1.1×	988 1.0×	1.6k 2.1×	615 0.9×	756 1.2×	120	3.2k
LM Nadler United States	28	1.8k 1.4×	1.2k 1.2×	995 1.3×	440 0.7×	895 1.4×	54	3.3k

Countries citing papers authored by James E. Wooldridge

Since Specialization

Citations

This map shows the geographic impact of James E. Wooldridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Wooldridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Wooldridge more than expected).

Fields of papers citing papers by James E. Wooldridge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Wooldridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Wooldridge. The network helps show where James E. Wooldridge may publish in the future.

Co-authorship network of co-authors of James E. Wooldridge

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Wooldridge. A scholar is included among the top collaborators of James E. Wooldridge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Wooldridge. James E. Wooldridge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Negrão, Marcelo V., Vassiliki A. Papadimitrakopoulou, Alda L. Tam, et al.. (2022). Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC. JTO Clinical and Research Reports. 4(3). 100423–100423. 6 indexed citations

Badeaux, Mark, Annah S. Rolig, Melissa J. Kasiewicz, et al.. (2021). Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth. Cancer Immunology Research. 9(4). 415–429. 15 indexed citations

Raje, Noopur, Edward A. Faber, Paul G. Richardson, et al.. (2016). Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 22(23). 5688–5695. 22 indexed citations

Rosen, Lee S., Jonathan W. Goldman, Alain P. Algazi, et al.. (2016). A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. Clinical Cancer Research. 23(8). 1910–1919. 57 indexed citations

Ganjoo, Kristen N., Sven de Vos, Brad Pohlman, et al.. (2014). Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma. Leukemia & lymphoma. 56(1). 42–48. 28 indexed citations

Forero‐Torres, Andres, Sven de Vos, Brad Pohlman, et al.. (2012). Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma. Clinical Cancer Research. 18(5). 1395–1403. 54 indexed citations

Ghobrial, Irene M., Nikhil C. Munshi, Brianna Harris, et al.. (2011). A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. American Journal of Hematology. 86(7). 573–578. 19 indexed citations

Zent, Clive S., Bruce A. Smith, Zuhair K. Ballas, et al.. (2011). Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leukemia & lymphoma. 53(2). 211–217. 70 indexed citations

Tobinai, Kensei, Michinori Ogura, Yukio Kobayashi, et al.. (2010). Phase I study of LY2469298, an Fc‐engineered humanized anti‐CD20 antibody, in patients with relapsed or refractory follicular lymphoma. Cancer Science. 102(2). 432–438. 25 indexed citations

10.

Coiffier, Bertrand, Stéphane Leprêtre, Lars Møller Pedersen, et al.. (2007). Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 111(3). 1094–1100. 287 indexed citations

11.

Shi, Huidong, Juyuan Guo, Deiter J. Duff, et al.. (2006). Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis. 28(1). 60–70. 66 indexed citations

12.

Chand, Vikram K., et al.. (2006). Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. Leukemia & lymphoma. 47(4). 657–663. 14 indexed citations

13.

Link, Brian K., Zuhair K. Ballas, Daniel Weisdorf, et al.. (2006). Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma. Journal of Immunotherapy. 29(5). 558–568. 124 indexed citations

14.

Wooldridge, James E., et al.. (2005). Improved Survival of Follicular Lymphoma Patients in the United States. Journal of Clinical Oncology. 23(22). 5019–5026. 199 indexed citations

15.

Jahrsdörfer, Bernd, et al.. (2005). Serum Alters the Uptake and Biologic Activity of CpG Oligodeoxynucleotides in B Cell Chronic Lymphocytic Leukemia. Oligonucleotides. 15(1). 51–59. 2 indexed citations

16.

Racila, Emilian, Wen‐Kai Weng, James E. Wooldridge, et al.. (2005). A Polymorphism in the C1qA Component of Complement Correlates with Prolonged Complete Remission Following Rituximab Therapy of Follicular Lymphoma.. Blood. 106(11). 778–778. 2 indexed citations

17.

Wooldridge, James E. & George J. Weiner. (2003). CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. Current Opinion in Oncology. 15(6). 440–445. 44 indexed citations

18.

Wooldridge, James E. & Brian K. Link. (2003). Post-treatment surveillance of patients with lymphoma treated with curative intent. Seminars in Oncology. 30(3). 375–381. 5 indexed citations

19.

Wooldridge, James E., et al.. (2001). Corticosteroids in advanced cancer.. PubMed. 15(2). 225–34; discussion 234. 45 indexed citations

20.

Wooldridge, James E., et al.. (1997). T-cell activation induced by anti-CD3 × anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand. Cancer Immunology Immunotherapy. 45(3-4). 174–179. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact